262 related articles for article (PubMed ID: 25437562)
21. Could B7-H4 serve as a target to activate anti-cancer immunity?
Wang L; Heng X; Lu Y; Cai Z; Yi Q; Che F
Int Immunopharmacol; 2016 Sep; 38():97-103. PubMed ID: 27258187
[TBL] [Abstract][Full Text] [Related]
22. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
23. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of mouse SP2/0 myeloma cell growth by the B7-H4 protein vaccine.
Mu N; Liu N; Hao Q; Xu Y; Li J; Li W; Wu S; Zhang C; Su H
BMB Rep; 2014 Jul; 47(7):399-404. PubMed ID: 24314141
[TBL] [Abstract][Full Text] [Related]
25. B7-H4, a promising target for immunotherapy.
Wang JY; Wang WP
Cell Immunol; 2020 Jan; 347():104008. PubMed ID: 31733822
[TBL] [Abstract][Full Text] [Related]
26. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
27. The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival.
He C; Qiao H; Jiang H; Sun X
Clin Dev Immunol; 2011; 2011():695834. PubMed ID: 22013483
[TBL] [Abstract][Full Text] [Related]
28. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells.
Lee JS; Scandiuzzi L; Ray A; Wei J; Hofmeyer KA; Abadi YM; Loke P; Lin J; Yuan J; Serreze DV; Allison JP; Zang X
J Immunol; 2012 Oct; 189(8):4165-74. PubMed ID: 22972920
[TBL] [Abstract][Full Text] [Related]
29. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
32. Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
Dangaj D; Scholler N
Methods Mol Biol; 2015; 1319():37-49. PubMed ID: 26060068
[TBL] [Abstract][Full Text] [Related]
33. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.
Ohaegbulam KC; Liu W; Jeon H; Almo SC; Zang X
Oncotarget; 2017 Oct; 8(47):82740-82753. PubMed ID: 29137299
[TBL] [Abstract][Full Text] [Related]
34. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
35. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
36. B7-H4 expression in various tumors determined using a novel developed monoclonal antibody.
Qian Y; Shen L; Cheng L; Wu Z; Yao H
Clin Exp Med; 2011 Sep; 11(3):163-70. PubMed ID: 21190056
[TBL] [Abstract][Full Text] [Related]
37. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.
John P; Pulanco MC; Galbo PM; Wei Y; Ohaegbulam KC; Zheng D; Zang X
Nat Commun; 2022 May; 13(1):2506. PubMed ID: 35523809
[TBL] [Abstract][Full Text] [Related]
38. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
39. [Preparation of anti-B7-H4 monoclonal antibody to investigate B7-H4 expression in pancreatic cancer].
Hong B; Qian Y; Yao HP
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):511-6. PubMed ID: 24167131
[TBL] [Abstract][Full Text] [Related]
40. T cell coinhibition and immunotherapy in human breast cancer.
Janakiram M; Abadi YM; Sparano JA; Zang X
Discov Med; 2012 Oct; 14(77):229-36. PubMed ID: 23114578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
